Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...

In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...

In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...

In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...

When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...

Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.

Unpack why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how ...

Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...

Mallon: The survey does highlight that principally prolonged contract and budget negotiations are probably the top barriers ...

In today’s ACT Brief, we look at how community research sites can stay competitive under efficiency pressure, why 2026 is ...

In today’s ACT Brief, we examine how community research sites can stay competitive under rising efficiency pressures, why ...

Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...